| Literature DB >> 29173203 |
Jing Guo1, Julie A Lovegrove2, D Ian Givens1.
Abstract
The ability to synthesise sufficient vitamin D through sunlight in human subjects can be limited. Thus, diet has become an important contributor to vitamin D intake and status; however, there are only a few foods (e.g. egg yolk, oily fish) naturally rich in vitamin D. Therefore, vitamin D-enriched foods via supplementing the animals' diet with vitamin D or vitamin D fortification of foods have been proposed as strategies to increase vitamin D intake. Evidence that cholecalciferol (vitamin D3) and calcifediol (25(OH)D3) content of eggs, fish and milk increased in response to vitamin D3 supplementation of hens, fish or cows' diets was identified when vitamin D-enrichment studies were reviewed. However, evidence from supplementation studies with hens showed only dietary 25(OH)D3, not vitamin D3 supplementation, resulted in a pronounced increase of 25(OH)D3 in the eggs. Furthermore, evidence from randomised controlled trials indicated that a 25(OH)D3 oral supplement could be absorbed faster and more efficiently raise serum 25(OH)D concentration compared with vitamin D3 supplementation. Moreover, evidence showed the relative effectiveness of increasing vitamin D status using 25(OH)D3 varied between 3·13 and 7·14 times that of vitamin D3, probably due to the different characteristics of the investigated subjects or study design. Therefore, vitamin D-enrichment or fortified foods using 25(OH)D3 would appear to have advantages over vitamin D3. Further well-controlled studies are needed to assess the effects of 25(OH)D3 enriched or fortified foods in the general population and clinical patients.Entities:
Keywords: 25(OH)D3 25-hydroxyvitamin D3; RCT randomised controlled trial; 25(OH)D3; Enrichment; Fortification; Vitamin D deficiency; Vitamin D3
Mesh:
Substances:
Year: 2017 PMID: 29173203 PMCID: PMC6088524 DOI: 10.1017/S0029665117004062
Source DB: PubMed Journal: Proc Nutr Soc ISSN: 0029-6651 Impact factor: 6.297
Summary of enrichment studies investigating the impact of adding vitamin D to the diet of laying hens on the vitamin D content of egg yolks
| References | Vitamin D supplement (μg/kg) | Feeding duration (weeks) | Vitamin D concentration of egg yolk (μg/100 g) | ||
|---|---|---|---|---|---|
| Vitamin D3 | 25(OH)D3 | Vitamin D3 | 25(OH)D3 | ||
| Mattila | 26·6 | – | 6 | 1·4 | 0·5 |
| 62·4 | – | 6 | 3·5 | 0·9 | |
| 216·0 | – | 6 | 22·0 | 1·5 | |
| Mattila | 280·0 | – | 4 | 30·0 | 1·9 |
| Mattila | 62·5 | – | 4 | 3·8 | – |
| 150·0 | – | 4 | 13·6 | – | |
| 375·0 | – | 4 | 33·7 | – | |
| Browning and Cowieson( | 62·5 | – | 9 | 6·5 | 1·6 |
| 125·0 | – | 9 | 10·5 | 2·1 | |
| 250·0 | – | 9 | 26·2 | 3·0 | |
| Yao | 55·0 | – | 3 | 3·0 | – |
| 242·5 | – | 3 | 21·6 | – | |
| 430·0 | – | 3 | 41·0 | – | |
| 617·5 | – | 3 | 60·3 | – | |
| 2555·0 | – | 3 | 870·4 | – | |
| Browning and Cowieson( | 62·5 | 0 | 9 | 6·5 | 1·6 |
| 62·5 | 34·5 | 9 | 6·0 | 3·3 | |
| 62·5 | 69·0 | 9 | 4·9 | 4·5 | |
| 125·0 | 0 | 9 | 10·5 | 2·1 | |
| 125·0 | 34·5 | 9 | 7·4 | 4·5 | |
| 125·0 | 69·0 | 9 | 8·1 | 5·8 | |
| 250·0 | 0 | 9 | 26·2 | 3·0 | |
| 250·0 | 34·5 | 9 | 23·6 | 3·7 | |
| 250·0 | 69·0 | 9 | 30·9 | 8·1 | |
| Mattila | – | 55·0 | 6 | ≤0·2 | 2·1 |
| – | 122·0 | 6 | ≤0·2 | 4·3 | |
| Duffy | 37·5 | – | 4 | 1·0 | 1·9 |
| 75·0 | – | 4 | 2·0 | 1·9 | |
| 37·5 | 37·5 | 4 | 1·3 | 3·6 | |
| 75·0 | 4 | 0·7 | 4·4 | ||
25(OH)D3, 25-hydroxyvitamin D3.
Vitamin D content per egg.
Summary of enrichment studies investigating the impact of vitamin D supplemental fish feeding on vitamin D content of fish
| References | Vitamin D3 supplement (μg/kg) | Feeding duration (weeks) | Vitamin D3 of fish (μg/100 g) |
|---|---|---|---|
| Horvli | 40 | 11 | 1 (fillet) |
| 2210 | 11 | 21 (fillet) | |
| 28 680 | 11 | 210 (fillet) | |
| Vielma | 62·5 | 12 | 1 (liver) |
| 6250 | 12 | 73 (liver) | |
| 62 500 | 12 | 6900 (liver) | |
| Mattila | 89 | 16 | 6–15 (fish fillet) |
| 174 | 16 | 6–10 (fish fillet) | |
| 539 | 16 | 7–16 (fish fillet) | |
| Graff | 200 | 9 | ≤25 (whole fish) |
| 5000 | 9 | 80 (whole fish) | |
| 57 000 | 9 | 650 (whole fish) |
Estimated from graph.
Summary of enrichment studies investigating the impact of vitamin D supplementation to the diet of dairy cows on vitamin D content of milk
| References | Supplements to diet (μg/d) | Vitamin D concentration of milk (μg/l) | ||||
|---|---|---|---|---|---|---|
| Vitamin D3 | 25(OH)D3 | Feeding duration | Vitamin D3 | 25(OH)D3 | 1,25(OH)2 D3 | |
| Hollis | 100 | – | NA | 0·04 | 0·37 | 0·01 |
| 1000 | – | NA | 0·32 | 0·68 | 0·004 | |
| Reeve | 375 | – | 30 d | 0·28 | 0·15 | 0·01 |
| Mcdermott | 0 | – | 14 weeks | 0·08 | 0·25 | 0·10 |
| 250 | – | 14 weeks | 0·20 | 0·43 | 0·03 | |
| 1250 | – | 14 weeks | 0·15 | 0·75 | 0·13 | |
| 6250 | – | 14 weeks | 0·33 | 0·93 | 0·10 | |
| Weiss | 450 | – | 13 d before calving | 0·33–0·47 | 0·36–1·02 | – |
| – | DCAD + 6000 | 13 d before calving | – | 0·61–3·69 | – | |
25(OH)D3, 25-hydroxyvitamin D3; 1,25(OH)2D3, 1,25 dihydroxyvitamin D3; DCAD, dietary cation–anion difference of −138 mEq/kg.
Summary of study details and serum 25, hydroxyvitamin D (25(OH)D) concentration in long-term randomised controlled trials with calcifediol (25 hydroxyvitamin D3 (25(OH)D3)) supplementation in adults (order by year)
| References | Subjects characteristics (trail time during the year, subjects (sex), age, BMI) | 25(OH)D3 supplementation group | Control group (if available) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Duration | 25(OH)D3 treatment | Baseline 25(OH)D (nmol/l) | Endpoint 25(OH)D (nmol/l) | Duration | Vitamin D3 treatment | Baseline 25(OH)D (nmol/l) | Endpoint 25(OH)D (nmol/l) | ||||
| Hahn | Whole year, patients (women and men) with glucocorticoid-induced osteopenia | 18 months | 40 µg/d + 500 mg calcium/d | 9 | 39 | 205 | |||||
| Barger-Lux | January–April, men | 4 weeks | 10 µg/d | 7 | 67 | 107 | 8 weeks | 25 µg/d | 13 | 67 | 96 |
| 4 weeks | 20 µg/d | 6 | 67 | 143 | 8 weeks | 250 µg/d | 10 | 67 | 213 | ||
| 4 weeks | 50 µg/d | 4 | 67 | 273 | 8 weeks | 1250 µg/d | 14 | 67 | 710 | ||
| Jean | March–September, haemodialysis patients (women and men) 67 years, BMI (NA) | 6 months | 16 µg /d | 149 | 30 | 126 | |||||
| Cavalli | April–July, postmenopausal women | 12 weeks | 125 µg/week + | 25 | 50 | 76 | |||||
| 12 weeks | 250 µg/month + | 28 | 51 | 70 | |||||||
| 12 weeks | 500 µg/month + | 27 | 52 | 77 | |||||||
| Russo | January–April, women (7 premenopausal and 11 postmenopausal), 24–72 years, 24 kg/m2 | 16 weeks | 500 µg/month | 18 | 45 | 105 | |||||
| Cashman | January–April, women and men, 57 years, 29 kg/m2 | 10 weeks | 20 µg/d | 12 | 38 | 135 | 10 weeks | 20 µg/d | 13 | 50 | 69 |
| Jetter | January–July, postmenopausal women 50–70 years, 18–29 kg/m2 | 16 weeks | 20 µg/d | 5 | 31 | 173 | 16 weeks | 20 µg/d | 5 | 35 | 77 |
| Catalano | September–March, osteopenic and dyslipidaemic postmenopausal women | 24 weeks | 140 µg once weekly | 29 | 56 | 126 | 24 weeks | 140 µg once weekly | 28 | 51 | 61 |
| Banon | Whole year, patients (women and men) had HIV-infected, 44 years, 15–44 kg/m2 | Summer | 400 µg once/month | 123 | 37 | 86 | Summer | NA | 242 | 53 | 99 |
| Fall | 400 µg once/month | 123 | 37 | 69 | Fall | NA | 242 | 53 | 84 | ||
| Winter | 400 µg once/month | 123 | 37 | 45 | Winter | NA | 242 | 53 | 55 | ||
| Spring | 400 µg once/month | 123 | 37 | 57 | Spring | NA | 242 | 53 | 78 | ||
| Ortego-Jurado | Whole year, patients (women and men) had autoimmune diseases, undergoing glucocorticoids therapy, 56 years, 28 kg/m2 | Spring–summer | 8·85 µg/d | 49 | NA | 84 | Spring–summer | 20 µg/d | 86 | NA | 71 |
| Fall–winter | 8·85 µg/d | 49 | NA | 89 | Fall–winter | 20 µg/d | 86 | NA | 61 | ||
| Navarro-Valverde | Whole year, postmenopausal osteoporotic women, 67 years, 26 kg/m2 | 6 months | 20 µg/d | 10 | 37 | 161 | 6 months | 20 µg/d | 10 | 41 | 80 |
| 12 months | 20 µg/d | 10 | 37 | 188 | 12 months | 20 µg/d | 10 | 41 | 86 | ||
| 6 months | 266 µg once/week | 10 | 38 | 214 | |||||||
| 12 months | 266 µg once/week | 10 | 38 | 233 | |||||||
| 6 months | 266 µg once/2 weeks | 10 | 40 | 165 | |||||||
| 12 months | 266 µg once/2 weeks | 10 | 40 | 211 | |||||||
NA, not available.
Estimated from graph.
Same study of (Jetter et al.()) and (Bischoff-Ferrari et al.()).
Study has measured vitamin D status as 25(OH)D3.
Summary of randomised controlled trials with both calcifediol (25 hydroxyvitamin D3 (25(OH)D3)) and vitamin D3 in adults to calculate the relative effectiveness of 25(OH)D3 and vitamin D3 supplementation in raising serum 25, hydroxyvitamin D (25(OH)D) level
| References | Treatment (dose, duration) | Serum 25(OH)D raising (nmol/l) per 1 μg | Relative effectiveness |
|---|---|---|---|
| Cashman | 20 µg 25(OH)D3/d × 10 weeks | 4·82a | 4·99 |
| 20 µg vitamin D3/d × 10 weeks | 0·97b | ||
| Jetter | 20 µg 25(OH)D3/d × 15 weeks | 7·12a | 3·40 |
| 20 µg vitamin D3/d × 15 weeks | 2·51b | ||
| Catalano | 140 µg 25(OH)D3/week × 24 weeks | 0·50a | 7·14 |
| 140 µg vitamin D3/week × 24 weeks | 0·07b | ||
| Navarro-Valverde | 20 µg 25(OH)D3/d × 6 months | 6·19a | 3·13 |
| 20 µg vitamin D3/d × 6 months | 1·98b | ||
| 20 µg 25(OH)D3/d × 12 months | 7·54a | 3·29 | |
| 20 µg vitamin D3/d × 12 months | 2·29b |
Dose–response factor = Δ serum/plasma (mmol/l)/dose (μg).
Relative effectiveness = a/b within same study.